Trileptal and Lung neoplasm malignant - a phase IV clinical study of FDA data

Summary:

Lung neoplasm malignant is reported as a side effect among people who take Trileptal (oxcarbazepine), especially for people who are male, 60+ old, also take Glucophage, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Lung neoplasm malignant when taking Trileptal. It is created by eHealthMe based on reports of 22,012 people who have side effects when taking Trileptal from the FDA, and is updated regularly.

What is Trileptal?

Trileptal has active ingredients of oxcarbazepine. It is often used in bipolar disorder. eHealthMe is studying from 23,558 Trileptal users. Check the latest studies of Trileptal.

What is Lung neoplasm malignant?

Lung neoplasm malignant (cancer tumour of lung) is found to be associated with 1,146 drugs and 928 conditions by eHealthMe. Check the latest studies of Lung neoplasm malignant.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

22,012 people reported to have side effects when taking Trileptal.
Among them, 14 people (0.06%) have Lung neoplasm malignant.

Could Trileptal cause Lung neoplasm malignant?

Among these 14 people:

What is the gender of people who have Lung neoplasm malignant when taking Trileptal? *

female: 50 %
male: 50 %

What is the age of people who have Lung neoplasm malignant when taking Trileptal? *

What are other drugs people take besides Trileptal? *

What are other side effects people have besides Lung neoplasm malignant? *

Pneumonia: 4 people, 28.57%
Weakness: 3 people, 21.43%
Drug Ineffective: 2 people, 14.29%
Memory Loss: 2 people, 14.29%
Dyspnea (difficult or laboured breathing): 2 people, 14.29%
Difficulty In Walking: 2 people, 14.29%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 2 people, 14.29%
Confusional State: 2 people, 14.29%
Speech Disorder: 2 people, 14.29%
Rash Pruritic (redness with itching): 2 people, 14.29%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 21.43%
High Blood Pressure: 2 people, 14.29%
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 2 people, 14.29%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 2 people, 14.29%
High Blood Cholesterol: 1 person, 7.14%
Diabetes: 1 person, 7.14%
Depression: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Trileptal and have Lung neoplasm malignant?

- Check whether Lung neoplasm malignant is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Trileptal:

Trileptal (23,558 reports)

Browse all side effects of Trileptal:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lung neoplasm malignant:

Lung neoplasm malignant (1,146 drugs)

Browse all the conditions that are associated with Lung neoplasm malignant:

Lung neoplasm malignant (928 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on oxcarbazepine (the active ingredients of Trileptal) and Trileptal (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.